DiscoveRx Corporation Develops a Highly Sensitive and Quantitative Fluorescence Assay for PI3 Kinase

Release date: 3/3/2008

Fremont, CA - March 03, 2008 - DiscoveRx Corporation, a leading provider of Kinase assay technology, today announced the development for a rapid, quantitative fluorescence detection assay for PI3 Kinase suitable for HTS applications. PI3-Kinases have been linked to an extraordinarily diverse group of cellular functions, including cell growth, proliferation, differentiation, motility, survival and intracellar trafficking. Commonly used methods for kinase screening either rely on antibody detection of a phospho-epitope, or monitoring ATP depletion as the result of kinase activity in vitro. These assays tend to be less sensitive, less versatile and more complicated to miniaturize.

We have optimized our ADP Hunter HS assay for enhanced signal to background and sensitivity with PI3-Kinase. The advantage of this assay over other formats is that it generates a positive readout in direct proportion to ADP accumulated. This is particularly useful in determining kinase and inhibitor kinetics such as substrate Km and inhibitor Ki. In our optimized assay, we observed excellent sensitivity with PI3-Kinase compared to antibody-based FRET -readout assays.

"Finally, we now can address a long time difficult target in Drug Discovery. The ADP Hunter HS based PI3-K assay has been shown to give the highest degree of sensitivity and simplicity inthe market" said Dr. Anna Christensen, DiscoveRx Product manager for Kinases."

About DiscoveRx Corporation
Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. The Company pioneered the use of β-galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and many of their innovative products have been widely adopted in pharmaceutical and biotech drug screening laboratories worldwide. For more information on DiscoveRx products, please visit www.discoverx.com.

Contact
DiscoveRx Corporation
Sailaja Kuchibhatla
tel | 510.979.1415 x104
skuchibhatla@discoverx.com
www.discoverx.com